Clinical bottom line
Rosacea is a chronic inflammatory skin condition characterized by facial erythema, papules, pustules, and telangiectasia. Recent advancements in topical treatments have expanded the therapeutic options available to clinicians. This evidence digest reviews the efficacy and safety of these new treatments, providing insights into their potential role in clinical practice.
What the evidence shows
Recent studies have highlighted several new topical agents for rosacea, including ivermectin, brimonidine, and oxymetazoline. A systematic review by van Zuuren et al. (2019) evaluated the efficacy of ivermectin 1% cream, demonstrating significant improvements in inflammatory lesion counts and patient-reported outcomes compared to placebo (PMID: 31184798). Another randomized controlled trial by Fowler et al. (2017) assessed brimonidine gel 0.33%, showing its effectiveness in reducing facial erythema with a rapid onset of action (PMID: 28192657). Oxymetazoline cream 1% has also been studied, with Draelos et al. (2018) reporting its efficacy in reducing persistent facial erythema over a 12-week period (PMID: 29985485).
Caveats and uncertainty
While these new treatments offer promising results, several caveats must be considered. The long-term safety profiles of these agents remain under investigation, and their efficacy may vary based on individual patient characteristics and severity of rosacea. Additionally, the studies often involve small sample sizes and short follow-up periods, which may limit the generalizability of the findings. It is crucial for clinicians to weigh these factors when considering new treatments for their patients.
How this may change practice
The introduction of these new topical treatments provides clinicians with additional options for managing rosacea, particularly for patients who may not respond well to traditional therapies. The rapid action of brimonidine gel and the sustained efficacy of ivermectin and oxymetazoline creams can enhance patient satisfaction and adherence to treatment. Clinicians should remain informed about ongoing research and emerging data to optimize treatment strategies for rosacea.